The National Comprehensive Cancer Network (NCCN) is a network of oncology healthcare providers who work together to develop best practice guidelines for the delivery of cancer care. Given the increasing use of testing for mutations in several inherited cancer genes at one time (called “multi-gene panel testing”), the Breast/Ovarian and Colorectal Panels sought to provide medical management guidance when using this testing approach. To access current NCCN guidelines, visit: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Breast and Ovarian (v2.2016)
Cancer risk management recommendations for some of the newer inherited breast and ovarian cancer genes were recently added. Based on emerging data, risk-reducing salpingo-oophorectomy became a consideration for women with mutations in BRIP1, RAD51C and RAD51D. Also, risk-reducing mastectomy became a consideration for women with a PALB2 mutation.